Connor, Clark & Lunn Investment Management (CC&L)’s KalVista Pharmaceuticals KALV Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-22,949
| Closed | -$266K | – | 1516 |
|
|
2024
Q3 | $266K | Buy |
22,949
+12,245
| +114% | +$142K | ﹤0.01% | 1275 |
|
|
2024
Q2 | $126K | Sell |
10,704
-57,501
| -84% | -$677K | ﹤0.01% | 1298 |
|
|
2024
Q1 | $809K | Sell |
68,205
-42,717
| -39% | -$507K | ﹤0.01% | 945 |
|
|
2023
Q4 | $1.36M | Buy |
110,922
+6,254
| +6% | +$76.6K | 0.01% | 770 |
|
|
2023
Q3 | $1.01M | Sell |
104,668
-3,307
| -3% | -$31.8K | 0.01% | 812 |
|
|
2023
Q2 | $972K | Buy |
107,975
+8,104
| +8% | +$72.9K | ﹤0.01% | 803 |
|
|
2023
Q1 | $785K | Buy |
99,871
+6,458
| +7% | +$50.8K | ﹤0.01% | 779 |
|
|
2022
Q4 | $631K | Sell |
93,413
-2,173
| -2% | -$14.7K | ﹤0.01% | 815 |
|
|
2022
Q3 | $1.39M | Buy |
95,586
+29,704
| +45% | +$431K | 0.01% | 578 |
|
|
2022
Q2 | $648K | Buy |
65,882
+42,989
| +188% | +$423K | ﹤0.01% | 718 |
|
|
2022
Q1 | $337K | Buy |
22,893
+6,845
| +43% | +$101K | ﹤0.01% | 850 |
|
|
2021
Q4 | $212K | Buy |
16,048
+4,161
| +35% | +$55K | ﹤0.01% | 965 |
|
|
2021
Q3 | $207K | Buy |
+11,887
| New | +$207K | ﹤0.01% | 941 |
|